Inflammatory Glycogen Produced by Gut Microbes Contributes to Neurodegeneration

Why It Matters

The finding links gut microbial metabolism directly to neuroinflammatory pathways, opening a novel therapeutic target for ALS, FTD, and possibly other age‑related neurodegenerative diseases.

Key Takeaways

• Gut bacteria synthesize inflammatory glycogen linked to neurodegeneration
• C9ORF72 mutation amplifies glycogen‑driven immune response
• Enzymatic glycogen removal improves survival in mouse ALS model
• 68% ALS patients' stool contained inflammatory glycogen
• Targeting microbial glycogen offers potential therapeutic avenue

Pulse Analysis

The gut‑brain axis has emerged as a critical frontier in neurodegenerative research, with microbial metabolites now recognized as active participants in brain health. While short‑chain fatty acids and bile acids have dominated headlines, this study spotlights glycogen—a polysaccharide traditionally viewed as an energy reserve—as a pro‑inflammatory agent when produced by specific gut commensals. By leveraging metatranscriptomic profiling, researchers traced the glycogen biosynthesis pathway to ten phylogenetically diverse bacterial strains, suggesting that the metabolic capacity of the microbiome can directly modulate systemic immune tone and, consequently, neural inflammation.

In pre‑clinical models, the interaction between glycogen‑producing Parabacteroides merdae and C9ORF72‑deficient mice revealed a cascade of pathological events: heightened monocytosis, compromised blood‑brain barrier integrity, and infiltration of peripheral T cells into the central nervous system. Notably, enzymatic degradation of gut glycogen restored survival rates and dampened microglial activation, underscoring the causal role of this microbial product. These mechanistic insights move the field beyond associative studies, demonstrating that a single microbial metabolite can exacerbate genetic vulnerabilities and accelerate neurodegeneration.

Clinically, the detection of inflammatory glycogen in the majority of ALS stool samples—and its relative scarcity in healthy controls—positions it as a potential biomarker for disease stratification and therapeutic monitoring. Interventions could range from targeted antibiotics or phage therapy to enzymatic supplementation that neutralizes glycogen in the gut lumen. As the population ages, modulating the microbiome’s glycogen output may become a viable strategy to mitigate neuroinflammatory burden, warranting larger human trials and deeper exploration of diet‑microbe‑host interactions.